Spyre Therapeutics (SYRE) said late Monday that it has commenced an underwritten public offering of its shares.
Investors can also buy pre-funded warrants in lieu, the clinical-stage biotechnology firm said. It expects to grant underwriters a 30-day option to buy additional shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.